The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). Wh

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale,

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 20

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metab

Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Co

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just rep

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZ

Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,0

I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2

The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technica

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

An executive at Maze Therapeutics reported selling 15,000 shares on March 20, 2026, yielding a trans

• Maze Therapeutics stock is among today's weakest performers. What's behind MAZE decline?

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-con

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients,

One of Maze Therapeutics' executives exercised and sold 30,000 shares on March 10, 2026, generating

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE